SCHEMBL2835065

SCHEMBL2835065

Cc1nc(OC2CCOC2)ccc1Br

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.40
ERBB2 P04626 1/20 0.36
EPHA2 P29317 1/20 0.36
KDR P35968 1/20 0.36
EPHB4 P54760 1/20 0.36
GRM5 P41594 6/20 0.35
PDE10A Q9Y233 3/20 0.35
PDE2A O00408 2/20 0.35
PIK3CA P42336 2/20 0.34
ALK Q9UM73 1/20 0.33
DRD3 P35462 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
KCNH2 Q12809 1/20 0.33
ACACB O00763 1/20 0.33
MBOAT4 Q96T53 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833261 0.91 PIK3CA (0.38) LRRK2GRM5PDE10APDE2APIK3CA
SCHEMBL30602477 0.83 ERBB2 (0.39) LRRK2ERBB2EPHA2KDREPHB4
SCHEMBL29130963 0.83 ERBB2 (0.39) LRRK2ERBB2EPHA2KDREPHB4
SCHEMBL19962929 0.82 GPR119 (0.37) PIK3CAACACBMBOAT4
SCHEMBL16178461 0.82 LRRK2 (0.40) LRRK2GRM5PDE10APDE2APIK3CA
SCHEMBL19963007 0.80 BRD4 (0.36) LRRK2
SCHEMBL19951531 0.80 BRD4 (0.38) LRRK2ACACB
SCHEMBL14938693 0.78 TXNRD1 (0.44) LRRK2GRM5PDE10APDE2ADRD3
SCHEMBL28390133 0.78 LRRK2 (0.37) LRRK2GRM5PDE10APDE2APIK3CA
SCHEMBL23967190 0.76 KCNH2 (0.37) LRRK2ERBB2EPHA2KDREPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 LRRK2 623/4885ERBB2 1615/4885EPHA2 2787/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 LRRK2 623/4885ERBB2 1615/4885EPHA2 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.